Literature DB >> 22561644

How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder.

R B Postuma1, A E Lang, J F Gagnon, A Pelletier, J Y Montplaisir.   

Abstract

Parkinsonism, as a gradually progressive disorder, has a prodromal interval during which neurodegeneration has begun but cardinal manifestations have not fully developed. A systematic direct assessment of this interval has never been performed. Since patients with idiopathic REM sleep behaviour disorder are at very high risk of parkinsonism, they provide a unique opportunity to observe directly the development of parkinsonism. Patients with idiopathic REM sleep behaviour disorder in an ongoing cohort study were evaluated annually with several quantitative motor measures, including the Unified Parkinson's Disease Rating Scale, Purdue Pegboard, alternate-tap test and timed up-and-go. Patients who developed parkinsonism were identified from this cohort and matched according to age to normal controls. Their results on motor testing from the preceding years were plotted, and then assessed with regression analysis, to determine when markers first deviated from normal values. Sensitivity and specificity of quantitative motor markers for diagnosing prodromal parkinsonism were assessed. Of 78 patients, 20 developed parkinsonism. On regression analysis, the Unified Parkinson's Disease Rating Scale first intersected normal values at an estimated 4.5 years before diagnosis. Voice and face akinesia intersected earliest (estimated prodromal interval = 9.8 years), followed by rigidity (4.4 years), gait abnormalities (4.4 years) and limb bradykinesia (4.2 years). Quantitative motor tests intersected normal values at longer prodromal intervals than subjective examination (Purdue Pegboard = 8.6 years, alternate-tap = 8.2, timed up-and-go = 6.3). Using Purdue Pegboard and the alternate-tap test, parkinsonism could be detected with 71-82% sensitivity and specificity 3 years before diagnosis, whereas a Unified Parkinson's Disease Rating Scale score >4 identified prodromal parkinsonism with 88% sensitivity and 94% specificity 2 years before diagnosis. Removal of action tremor scores improved sensitivity to 94% and specificity to 97% at 2 years before diagnosis (cut-off >3). Although distinction between conditions was often difficult, prodromal dementia with Lewy bodies appeared to have a slower progression than Parkinson's disease (prodromal interval = 6.0 versus 3.8 years). Using a cut-off of Unified Parkinson's Disease Rating Scale >3 (excluding action tremor), 25% of patients with 'still-idiopathic' REM sleep behaviour disorder demonstrated evidence of possible prodromal parkinsonism. Therefore, using direct assessment of motor examination before parkinsonism in a REM sleep behaviour disorder, we have estimated a prodromal interval of ∼4.5 years on the Unified Parkinson's Disease Rating Scale; other quantitative markers may detect parkinsonism earlier. Simple quantitative motor measures may be capable of reliably detecting parkinsonism, even before a clinical diagnosis can be made by experienced movement disorders neurologists.

Entities:  

Mesh:

Year:  2012        PMID: 22561644     DOI: 10.1093/brain/aws093

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  96 in total

1.  Movement disorders: Motor changes in sleep disorder signal prodromal parkinsonism.

Authors:  Katy Malpass
Journal:  Nat Rev Neurol       Date:  2012-06-12       Impact factor: 42.937

Review 2.  The heterozygous A53T mutation in the alpha-synuclein gene in a Chinese Han patient with Parkinson disease: case report and literature review.

Authors:  Wei-Xi Xiong; Yi-Min Sun; Rong-Yuan Guan; Su-Shan Luo; Chen Chen; Yu An; Jian Wang; Jian-Jun Wu
Journal:  J Neurol       Date:  2016-07-08       Impact factor: 4.849

Review 3.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

Review 4.  Rapid eye movement sleep behavior disorder and the link to alpha-synucleinopathies.

Authors:  Daniel A Barone; Claire Henchcliffe
Journal:  Clin Neurophysiol       Date:  2018-05-29       Impact factor: 3.708

5.  Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal?

Authors:  Ronald B Postuma; Jean-Francois Gagnon; Maria Tuineaig; Josie-Anne Bertrand; Veronique Latreille; Catherine Desjardins; Jacques Y Montplaisir
Journal:  Sleep       Date:  2013-11-01       Impact factor: 5.849

6.  Low muscle strength in late adolescence and Parkinson disease later in life.

Authors:  Helena Gustafsson; Jan Aasly; Stefan Stråhle; Anna Nordström; Peter Nordström
Journal:  Neurology       Date:  2015-04-03       Impact factor: 9.910

Review 7.  Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?

Authors:  Weidong Le; Jie Dong; Song Li; Amos D Korczyn
Journal:  Neurosci Bull       Date:  2017-09-02       Impact factor: 5.203

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

9.  Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease.

Authors:  Laura M Grant; Franziska Richter; Julie E Miller; Stephanie A White; Cynthia M Fox; Chunni Zhu; Marie-Francoise Chesselet; Michelle R Ciucci
Journal:  Behav Neurosci       Date:  2014-04       Impact factor: 1.912

10.  Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study.

Authors:  Ronald B Postuma; Alex Iranzo; Birgit Hogl; Isabelle Arnulf; Luigi Ferini-Strambi; Raffaele Manni; Tomoyuki Miyamoto; Wolfgang Oertel; Yves Dauvilliers; Yo-El Ju; Monica Puligheddu; Karel Sonka; Amelie Pelletier; Juan Santamaria; Birgit Frauscher; Smaranda Leu-Semenescu; Marco Zucconi; Michele Terzaghi; Masayuki Miyamoto; Marcus M Unger; Bertrand Carlander; Maria-Livia Fantini; Jacques Y Montplaisir
Journal:  Ann Neurol       Date:  2015-03-13       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.